Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization

Table 3 Univariate and multivariate analyses of overall survival for hepatocellular carcinoma patients undergoing transarterial chemoembolization (n = 224)

Variable	Univariate analysis	Multivariate analysis
	P value	HR (95%CI)	P value
Age (< 60/≥ 60 yr)	0.008
Sex (M/F)	0.118
WBC ( ≤ 10/> 10 × 109/L)	0.094
Neutrophil count ( ≤ 7/> 7 × 109/L)	0.038
Lymphocyte count ( ≤ 0.8/> 0.8 × 109/L)	0.088
CRP ( ≤ 8/> 8 mg/L)	< 0.001
PLT count ( ≤ 100/> 100 × 109/L)	0.472
ALT ( ≤ 40/> 40 U/L)	0.002	1.005 (1.001-1.009)	0.008
AST ( ≤ 45/> 45 U/L)	< 0.001
Albumin ( ≤ 35/> 35 g/L)	0.208
Total bilirubin ( ≤ 20.5/> 20.5 mmol/L)	< 0.001
ALP ( ≤ 110/> 110 IU/L)	< 0.001
AFP ( ≤ 400/> 400 ng/ml)	< 0.001
AFU ( ≤ 40/> 40 U/L)	0.042
Diameter of largest lesion (< 8/≥ 8 cm)	< 0.001
Tumor number (solitary/multiple)	0.025
Vascular invasion (absent/present)	< 0.001
Child-Pugh grade (A/B)	0.030
GPS (0/1/2)	< 0.001	1.697 (1.325-2.174)	< 0.001
Modified GPS (0/1/2)	< 0.001
NLR (0/1)	0.009
PLR (0/1/2)	0.553
PI (0/1/2)	< 0.001
PNI (0/1)	0.573
TNM stage (I/II/IIIa/IIIb/IVa/IVb)	< 0.001
CLIP score (0/1/2/3/4/5)	< 0.001	1.297 (1.1-1.53)	0.002
BCLC stage (A/B/C)	< 0.001

AFP: Alpha-fetoprotein level; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFU: Alpha-L-fucosidase; AST: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; CLIP: Cancer of the Liver Italian Program; CRP: C-reactive protein; GPS: Glasgow Prognostic Score; HR: Hazard ratio; NLR: Neutrophil-lymphocyte ratio; PI: Prognostic Index; PLR: Platelet-lymphocyte ratio; PLT: Platelet; PNI: Prognostic Nutritional Index; TNM: Tumor-node-metastasis; WBC: White blood cell count.